|
Patent landscape, scope, and claims: |
United States Patent 8,637,054 Patent Landscape: Scope of Claims for Latanoprost Ophthalmic Solution, Viscosity Limits, and Treatment Methods
Executive summary: U.S. Patent 8,637,054 claims a narrowly defined latanoprost ophthalmic solution defined by specific excipient levels, pH ~7.0, Brookfield viscosity 8–20 mPa·s, a topical dosing regimen for open-angle glaucoma/intraocular pressure reduction, and a packaging constraint (LDPE bottle with no additives). The claim set is structured to capture both composition (Claim 1), critical quality attributes (Claim 2), clinical use (Claims 3–4), and device/packaging (Claim 5). The estate’s practical value for enforcement is highest against products that match the exact excipient combination and concentrations and the viscosity and pH targets, with secondary reach for launch timing through paragraph IV-style challenges to composition and formulation patents tied to generic/biosimilar ophthalmic latanoprost offerings.
What does U.S. Patent 8,637,054 claim: scope of the latanoprost ophthalmic solution formulation?
Core scope (Claim 1)
Claim 1 is a composition claim for an ophthalmic solution containing, by stated concentration ranges/targets:
- Latanoprost: about 0.005% (w/v)
- Macrogol glycerol hydroxystearate 40 (Solutol-like surfactant): about 5% (w/v)
- Carbomer 974P: about 0.1% (w/v)
- Sodium EDTA: about 0.05% (w/v)
- PEG 4000: about 1% (w/v)
- Sorbitol: about 3.5% (w/v)
- Sodium hydroxide (pH adjustment)
- Water
- pH: about 7.0
Interpretive levers that matter in practice
- “about” language: Claim 1 uses “about” for each excipient, which typically broadens the infringement window compared with strict numeric endpoints, but still ties infringement to the claimed formulation identity (the same excipient set and relative levels).
- Excipient set specificity: The combination is not a generic “latanoprost with preservatives and buffers.” It forces inclusion of the named excipients: macrogol glycerol hydroxystearate 40, carbomer 974P, sodium EDTA, PEG 4000, sorbitol, plus water and NaOH for pH.
- pH limitation: “wherein the ophthalmic solution has a pH of about 7.0” creates an additional quality-attribute limitation. Products buffered to a different pH band can reduce infringement risk even if they match most excipient concentrations.
What Claim 1 does not claim
- No explicit claim to benzalkonium chloride (or other common preservatives) in your provided claim text.
- No explicit claim to sterility assurance, antioxidants, tonicity agent ratios beyond sorbitol, or specific manufacturing steps.
- No explicit claim to a specific concentration of latanoprost active in nanocarriers or special delivery system beyond the named surfactant/viscosity system.
Which formulations fall within the “about” boundaries for Claim 1?
In enforcement or generic design-around analysis, the relevant question is whether an accused formulation:
- contains latanoprost at ~0.005% w/v,
- uses macrogol glycerol hydroxystearate 40 at ~5% w/v,
- includes carbomer 974P at ~0.1% w/v,
- includes sodium EDTA at ~0.05% w/v,
- includes PEG 4000 at ~1% w/v,
- includes sorbitol at ~3.5% w/v, and
- achieves pH ~7.0.
Products missing any one of these named ingredients can argue non-infringement on “consisting of” style limitations (depending on claim drafting interpretation), while products using different excipients in the same roles face infringement risk if claim construction treats the excipient set as essential.
How do Claim 2’s Brookfield viscosity limits change infringement risk for U.S. 8,637,054?
Claim 2 depends on Claim 1
Claim 2 adds a rheology limitation:
- Brookfield viscosity at 25° C.: between 8 and 20 mPa·s
Practical impact
- Claim 2 introduces a measurable performance parameter. Even if a generic matches excipient identity and concentrations, a viscosity outside 8–20 mPa·s at 25°C can reduce infringement risk for Claim 2.
- Because Claim 2 depends on Claim 1, infringement of Claim 2 generally requires satisfying both the composition constraints of Claim 1 and the viscosity requirement.
Design-around pathway
- Adjusting carbomer grade, concentration, neutralization conditions (NaOH amount), polymer hydration state, or manufacturing shear can shift viscosity. If the accused product remains inside Claim 1 but outside Claim 2, it may still infringe Claim 1 while avoiding Claim 2.
What patent protection exists for treating glaucoma using Claim 1 composition (Claims 3–4)?
Claim 3: method for treating open-angle glaucoma or reducing intraocular pressure
Claim 3:
- includes administration of a solution of Claim 1 to an individual in need.
Claim 4: dosing regimen
Claim 4 specifies:
- topically administering one drop once a day to each eye in humans or animals.
Scope notes
- These are use claims tied to the Claim 1 composition. An accused product that does not practice the Claim 1 formulation cannot infringe Claims 3–4 as written.
- The topical regimen is explicit: one drop daily to each eye. An alternative dosing regimen or different instruction language could narrow infringement.
Commercial and regulatory relevance
- The method claims can be asserted even when the accused product is the same active ingredient (latanoprost) because infringement turns on what composition is administered and how it is administered.
- For generic approval, if the label differs (dosing instructions) or if a product is used off-label, enforcement still depends on claim elements being met by the accused conduct, not solely on the FDA label.
How does Claim 5’s LDPE bottle requirement affect packaging and product launch designs?
Claim 5 depends on Claim 1
Claim 5 requires:
- Single-use or multi-dose bottle made of LDPE containing no additives
- and containing the ophthalmic solution of Claim 1.
Impact on infringement
- Packaging-related limitations can create an additional non-infringement route. A competitor using glass, polypropylene, or LDPE with additives can argue it avoids Claim 5 even if composition and viscosity match.
- The phrase “containing no additives” introduces a materials-of-construction constraint. If an LDPE container includes any additive package (antioxidants, slip agents, UV stabilizers, pigments), the claim may not be met.
Litigation posture
- Claim 5 often becomes a key lever in settlement because packaging is controllable by manufacturing and because confirmatory evidence can be obtained from supplier documentation and extractables/leachables studies.
What is the overall claim hierarchy for U.S. Patent 8,637,054?
| Claim |
Type |
Key elements |
Most likely infringement trigger |
| 1 |
Composition |
Latanoprost ~0.005% + macrogol glycerol hydroxystearate 40 ~5% + carbomer 974P ~0.1% + sodium EDTA ~0.05% + PEG 4000 ~1% + sorbitol ~3.5% + water + NaOH + pH ~7.0 |
Products matching full excipient set and pH |
| 2 |
Composition quality attribute (dependent) |
Claim 1 + Brookfield viscosity 8–20 mPa·s at 25°C |
Rheology matches specified window |
| 3 |
Method of treatment (dependent) |
Claim 1 composition administered to treat OAG/reduce IOP |
Uses the claimed formulation |
| 4 |
Method of treatment with dose (dependent) |
Claim 3 + one drop once daily to each eye |
Labeling and practice align with regimen |
| 5 |
Packaging/device (dependent) |
Claim 1 solution in LDPE container with no additives |
Materials-of-construction and packaging selection |
What does the claim set imply about patent strength and enforceability for generic latanoprost solutions?
Strong points for enforcement
- Multiple composition-defining excipients at specified concentrations reduce prior-art overlap risk compared with broader “latanoprost + common preservatives/buffers” claims.
- Inclusion of pH and viscosity adds measurable constraints that can separate the claimed formulation from adjacent excipient systems.
- Packaging constraint (LDPE with no additives) provides an additional field for evidence-based infringement analysis.
Potential vulnerabilities (litigation and claim construction)
- If claim terms like “about” and Brookfield viscosity at 25°C invite measurement disputes, expert testimony can dominate.
- If competitors use different excipient substitutes or buffering systems that still meet performance requirements but differ from Claim 1’s ingredient list, infringement of Claim 1 can be contested.
Practical inference
The patent is likely most valuable against direct formulation copycats that try to reproduce the same excipient architecture and quality attributes rather than generic substitutes with different formulation science.
How does U.S. Patent 8,637,054 compare to typical latanoprost ophthalmic patent estates?
Typical landscape patterns
Latanoprost formulations in the US often include:
- preservative systems (commonly benzalkonium chloride),
- buffers (phosphate, borate, citrate),
- tonicity agents (sodium chloride and/or sorbitol),
- surfactants/solubilizers, and
- viscosity modifiers (carbomers, cellulosics).
This patent’s distinguishing features
- Explicit use of macrogol glycerol hydroxystearate 40 at ~5%.
- Use of PEG 4000 at ~1% alongside carbomer 974P.
- pH target ~7.0, rather than the more common neutral phosphate buffers.
- Rheology capture by Brookfield viscosity 8–20 mPa·s at 25°C.
- Packaging constraint around LDPE without additives.
This combination suggests a specific formulation design rather than a broad “latanoprost” platform claim.
When does U.S. Patent 8,637,054 lose exclusivity and how does that affect generic entry risk?
No USPTO filing, issue, or term-expiration dates were provided in the prompt, and a complete exclusivity timeline cannot be produced from the claim text alone.
If you proceed to build a launch-risk model, the relevant nodes will be:
- statutory patent expiration (20 years from earliest nonprovisional filing),
- any adjustment (AIA/USPTO delay),
- potential terminal disclaimers,
- and whether the patent is tied to an FDA-approved NDA/ANDA listing (Orange Book “patent expiration” fields).
Without those date inputs, an exclusivity timeline would be incomplete.
What is the Orange Book status of U.S. Patent 8,637,054 for latanoprost ophthalmic products?
No Orange Book listing identifiers (drug product, NDA/ANDA number, patent listing entry ID) were provided. A reliable status assessment cannot be constructed from the claim text alone.
What patent litigation scenarios would most likely involve U.S. 8,637,054?
Based on claim structure, the most common litigation fact patterns would be:
- Composition infringement: accused generic ophthalmic solution uses the same excipient set and concentrations, targets pH ~7.0, and falls within viscosity window.
- Rheology dispute: accused product matches composition but viscosity measurement at 25°C using Brookfield conditions falls outside 8–20 mPa·s.
- Method-of-use overlap: settlement focuses on whether labeling instructions match “one drop once daily to each eye,” and whether the product actually administers the claimed composition.
- Packaging carve-out: accused product uses LDPE but with additive package, or uses alternate plastics, changing the Claim 5 element.
How strong is the patent estate for U.S. 8,637,054 and what is the likely design-around space?
Likely design-around space
- Swap out one or more excipients (e.g., different solubilizer/solvent system instead of macrogol glycerol hydroxystearate 40; different high-molecular-weight polymer system instead of PEG 4000).
- Use different buffering systems that place the product pH materially outside ~7.0.
- Tune carbomer neutralization and polymer hydration to move viscosity outside 8–20 mPa·s at 25°C.
- Use packaging not meeting LDPE with no additives.
Most costly to replicate
The tight combination of excipient identities plus pH and viscosity makes full replication more difficult than genericizing only the active.
Key Takeaways
- U.S. Patent 8,637,054 is a narrow, formulation-specific patent covering a latanoprost ophthalmic solution with a defined excipient architecture, pH ~7.0, and a dependent Brookfield viscosity 8–20 mPa·s at 25°C.
- The patent expands beyond composition into use (open-angle glaucoma/IOP reduction; one drop once daily to each eye) and packaging (LDPE container with no additives).
- The strongest infringement case is against competitors that match all named excipients at the claimed levels and meet pH and viscosity and the LDPE/no-additives container requirement.
- Design-around is most plausible by changing any critical excipient, moving pH, moving viscosity, or using different packaging materials/additive formulations.
FAQs
-
What excipient changes would most likely avoid Claim 1 infringement for latanoprost solutions?
Any change that removes or materially replaces one of the named required excipients at the claimed “about” levels (macrogol glycerol hydroxystearate 40, carbomer 974P, sodium EDTA, PEG 4000, sorbitol) or shifts pH away from ~7.0.
-
Can a product infringe Claim 1 but not Claim 2?
Yes. Claim 2 depends on Claim 1 and adds the specific Brookfield viscosity 8–20 mPa·s at 25°C. Matching Claim 1’s formulation identity does not guarantee the viscosity window.
-
What is the most common way to avoid the method-of-use claims (Claims 3–4)?
Avoid administering the Claim 1 composition, and/or use a dosing regimen that does not meet “one drop a day to each eye” as practiced.
-
Does Claim 5 create a separate infringement risk for packaging even if formulation matches?
Yes. A competitor can potentially avoid Claim 5 by using non-LDPE packaging or LDPE with additives, even if the formulation matches Claim 1.
-
Is Brookfield viscosity a labeling or manufacturing parameter for enforcement?
It is both. Claim 2 ties to a measured attribute at 25°C, so manufacturing process and end-product testing can both be central in infringement or non-infringement proof.
References (APA)
- U.S. Patent No. 8,637,054.
More… ↓
⤷ Start Trial
|
